DECEMBER 22, 2015 December 22, 2015, Toronto, ON–Supreme Pharmaceuticals Inc. (the “Company“) (SPRWF – OTC) (“SL” – CSE) is pleased to announce that the Company has continued (the “Continuance“) out of the jurisdiction of the Business Corporations Act (British Columbia) and into the jurisdiction of the Canada Business Corporations Act (the “CBCA“) and has adopted […]
DECEMBER 10, 2015 December 10, 2015, Toronto, ON – Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (SPRWF – OTC) (“SL” – CSE) is pleased to announce on December 9, 2015, Health Canada conducted the Pre-License Inspection of Supreme’s hybrid greenhouse facility in Kincardine, Ontario. About Supreme Supreme is a Canadian publically traded company committed to […]
DECEMBER 03, 2015 December 3, 2015, Toronto, ON – Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (SPRWF – OTC) (“SL” – CSE) is pleased to announce Health Canada has scheduled a pre-license inspection of Supreme’s hybrid greenhouse facility in Kincardine, Ontario on December 9, 2015. About Supreme Supreme is a Canadian publically traded company committed […]
DECEMBER 02, 2015 December 2, 2015, Toronto, ON – Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (SPRWF – OTC) (“SL” – CSE) is pleased to announce a limited time incentive program (the “Incentive Program”) commencing December 7, 2015 to exercise 12,607,349 outstanding common share purchase warrants (the “April Warrants”) issued pursuant to the Company’s April 23, 2015 […]
NOVEMBER 19, 2015 Thursday, November 19 2015, Toronto, ON – Supreme Pharmaceuticals Inc. (the “Company” or “Supreme“) (OTC PINK:SPRWF)(CSE:SL) is pleased to announce the appointment of Navdeep Dhaliwal to the Company’s Board of Directors. Mr. Dhaliwal’s primary focus will be the development of Supreme’s go-to-market strategy in addition to corporate development and capital markets initiatives. […]
OCTOBER 14, 2015 October 14, 2014 – Supreme Pharmaceuticals Inc.(SPRWF – OTC) (“SL” – CSE) announced today that it has issued 4,100,000 stock options to directors, officers, employees and consultants.Each option entitles the holder to acquire one common share of the Company for a period of five years (3,900,000 options) or two years (200,000 options), at […]
JULY 30, 2015 Thursday July 30th, 2015, Toronto, ON – Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (SPRWF – OTC) (“SL” – CSE) is pleased to announce that it has closed a private placement financing (the “Financing”) for gross proceeds of $684,449.82. Upon closing the Financing, Supreme issued 4,026,469 units (“ Units”) at a price of $0.17 per Unit. Each […]
APRIL 23, 2015 Thursday, April 23, 2015, Toronto, ON – Supreme Pharmaceuticals Inc. (the “Company“) (SPRWF – OTC) (“SL” – CSE) is pleased to announce that it has closed its previously disclosed non-brokered private placement (the “Financing“) of secured convertible debentures (the “Debentures“). At closing, the Company issued $1,465,580 [all currency references are in Canadian dollars] […]
APRIL 17, 2015 Friday April 17, 2015, Toronto, ON – Supreme Pharmaceuticals Inc. (the “Company“) (SPRWF – OTC) (“SL” – CSE) announced today that it increased the size of its previously disclosed non-brokered private placement of secured convertible debentures (the “Financing“) in response to greater than anticipated investor demand and has closed the books on approximately $1.4 […]
FEBRUARY 09, 2015 February 9th, 2015, Toronto, ON – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWF – OTC) (“SL” – CSE) is pleased to announce it has completed its operational transition from British Columbia to Ontario in order to focus resources on the Kincardine facility. The transition allows the Company to reduce operating overhead and focus efforts […]